Will the Phase 3 trial "A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients" reach primary completion on or before May 31, 2027?

Resolves Yes if ClinicalTrials.gov record NCT07103668 (Suzhou Immunofoco Biotechnology Co., Ltd) shows an actual primary completion date on or before May 31, 2027. Registered date at generation: May 31, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By May 31, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.